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eat Chronic Back Painppropriateness of Long-rm

Opioids to
Treat Chronic Back PainCASE SCENARIO
A 55-year-old man presents to a pain clinic upon referral from his primary care
physician. His symptom is axial low back pain. His pain started approximately 1 year
earlier without a specific inciting event. He denies radiation of pain into the lower
extremities. There is no bowel or bladder involvement. There is no directional preference.
He reports pain “all the time,” with minimal specific exacerbating or relieving
factors. There is no medical-legal involvement. His medical history is significant for
hypertension, hypercholesterolemia, obesity, and sleep apnea. He is a divorced father
of 2 adult children. He is self-employed local truck driver, and his job also involves
some loading and unloading of boxes, although he describes the weight of the boxes as
“light.” He notes a decreased capacity to complete job-related activities but states that
the pain medication (sustained-release oxycodone, 80 mg twice a day) allows him to
work with minimal discomfort.
The physical examination is notable for diffusely limited lumbar range of motion
without a directional preference for pain reduction. Strength examination demonstrates
pain-limited weakness in the proximal bilateral lower extremities. There is no
abnormality of sensation or deep tendon reflexes. He has diffuse tenderness over the
lumbar paraspinal, quadratus lumborum laborum, gluteal, and piriformis muscles.
There is no tenderness over the sacroiliac joints. Gaenslen, flexion abduction external
rotation (FABER), slump, and straight-leg raising testing is negative. He is 5 ft, 11 in. tall
and weighs 230 lb.
His primary care physician ordered magnetic resonance imaging of the lumbar spine,
which demonstrated mild degeneration of multiple intervertebral disks without nerve root
compression. He has tried physical therapy, nonsteroidal anti-inflammatory drugs, and
cyclobenzaprine, without sustained relief. He has had bilateral lumbar selective nerve root
injections at L5 and S1 as well as bilateral facet injections at L4-5 and L5-S1 without
improvement. The primary care physician notes that the patient appears to have done well
on the sustained-release oxycodone, but the physician feels uncomfortable with continuing
to manage the pain with high doses of opioid pain medication. The physician believes that
the patient is taking the medication appropriately, but he concedes that he does not have a
formal program in place to help ensure that there is no medication diversion. He also is
concerned about the appropriateness of having his patient taking high doses of opioid
medications because his primary job task is driving.
What is your treatment recommendation, and how do you specifically plan to

address the issues related to long-term opioid use?

Michael Saulino, MD, PhD, Responds

The described patient fits with the criteria for chronic pain (1). He has undergone a
thorough diagnostic investigation. At least at present, further testing would not appear
warranted. While not completely exhaustive, there have been reasonable therapeutic
maneuvers. Further inquiry into the patient’s history should explore the nature of the
physical therapy sessions. It is conceivable that the rehabilitative strategies may have
been inappropriate. Perhaps the patient’s program focused on application of modalities
rather than therapeutic exercise, stretching, functional retraining and ergonomics. If these
latter strategies have not been employed, a referral to an alternative therapist would be
appropriate. The history does not comment upon other non-pharmacologic approaches to
chronic low back pain. Several options are available including acupuncture, massage
therapy, yoga, cognitive-behavioral therapy and spinal manipulation. The evidence basis
demonstrating the long-term effectiveness for these different therapies varies from fair to
good (2). With regards to medication therapy, the patient’s PCP has explored a rational
approach to date. Conceivably, alternative medications could be attempted. Notably
absent is an exposure to antidepressants, which represent another reasonable strategy (3).
Other potential agents include acetaminophen, NSAIDS, skeletal muscle relaxants and
anti-epileptic medications. These agents to not precisely fit this patient’s presentation
since the first three medication classes are typically used in acute pain syndromes while
the latter class is classically associated with chronic neuropathic pain. Each of these
medication categories is associated with unique trade-offs involving benefits, risks, and
costs (2). Conceivably, a trial of botulinum toxin injections if coupled with a functional
retraining strategy could be attempted but this approach similarly lacks substantive
evidence basis from randomized controlled trials (4). Additionally, given the duration of
the patient’s pain syndrome, a referral for neuromodulation (spinal cord stimulation or
intrathecal therapy) would not be unwarranted (5). However, given the patient’s positive
response to oral opioids, it is entirely appropriate to maintain the patient on this type of
medication. The remainder of this discourse will present the rationale for this opinion.
All therapeutic inventions in medicine require a risk benefit analysis by the treating
physician. This decision making is so fundamental to medical practice that is one of the
six core competencies defined by both the ACGME and ABMS is systems-based
practice, where risk-benefit analysis is specifically delineated as basic skill for trainees
and board-certified physicians alike (6). Perhaps, no other decision is medicine causes
more anxiety that prescribing opiates for patients with chronic, non-cancer pain (CNCP).
Concerns over diversion, misuse, dependence, addiction, monitoring and cost can make
the analysis of utilizing chronic opiate therapy (COT) troublesome for even experienced
practitioners (7).

The American Pain Society (APS) and the American Academy of Pain Medicine
(AAPM) have jointly put forth a set of guidelines for COT in CNCP (8). The primary

means of support for COT in this patient will be to determine how well this scenario fits
within these guidelines. The first set of recommendations describes patient selection and
risk stratification. Three elements within this set were put forth: (1) before initiating
COT, clinician should conduct a history, physical examination (PE) and appropriate
testing, including an assessment of risk of substance abuse, misuse or addiction; (2)
clinicians may consider COT as an option if CNCP is moderate or severe, pain is having
an adverse impact on function or quality of life, and potential therapeutic benefits
outweigh or are likely to outweigh potential harms; (3) a benefit-to-harm evaluation
including a history, PE and appropriate diagnostic testing should be performed and before
and on an ongoing basis during COT. In the described patient, the history, PE and
diagnostic testing have been undertaken in an exquisite and detailed manner. The history
does not put forth any episodes of abuse, misuse or addiction. These components should
be queried. In their absence, the first element is fully satisfied. Even if abuse, misuse,
diversion or addiction were to be elicited in this patient, COT would not be
contraindicated. Weaver and Schnoll (2002) delineate that the undertreatment of pain in
patients with addiction histories is more likely than adequate treatment to lead to drugseeking behavior in recovering addicts. Such individuals may require a greater level of
scrutiny and monitoring with potential consultation with addiction management
professionals. The first component of these guidelines would appear accomplished. With
regards to the second element, it is not clear from the history if a pain intensity or rating
was formally assessed. This assessment should be undertaken and documented (9).
Clearly, the patient’s pain complex is functionally limiting. Thus, regardless of a pain
rating, the second element would appear satisfied. Lastly, a benefit to harm analysis
should be explored. The history does not put forth any apparent adverse effects from the
patient’s current exposure to COT. As with all medications, potential untoward effects
can occur. For COT, this would include sedation, dizziness, nausea, vomiting,
constipation, physical dependence, tolerance, and respiratory depression (10). The patient
should be specifically queried as to presence or severity of these symptoms. The
prescribing physician may need to alter this treatment approach based on these adverse
effects. However, given their absence in the proposed patient, the purported benefit
would appear to outweigh the risk of harm.

There are several survey instruments available to clinicians that can assist in the decision
making relative to COT. One tool is Screener and Opioid Assessment for Patients with
Pain-Revised (SOAPP-R). This survey is self-reported questionnaire designed to predict
aberrant medication-related behaviors among chronic pain patients considered for COT.
The given history does not provide sufficient inquiry into these questions, so this
assessment cannot be formally utilized at this point. Another instrument that can be
utilized in this patient is the Opioid Risk Tool (ORT). This is another self-administered
questionnaire that utilizes personal and family history in an effort to predict aberrant
behavior. Again, the described history does not provide sufficient detail to apply this
instrument. Yet another screening tool that can be utilized the DIRE (Diagnosis,
Intractability, Risk and Efficacy) score. There is sufficient history to apply this tool to the
described patient. This analysis is reported in Table 1. Even with the most conservative

estimate, the patient would be considered a reasonable candidate for COT. The validity,
reliability, sensitivity and predicative value of these tools is considered fair to good (11).

One particular concern for this clinical scenario is driving while utilizing COT. Each state
regulates the parameters for routine driving licensure but, in general, physicians are
required to restrict driving in any individual where potential impairment is present. While
there is some data to suggest that the skills needed for safe driving are impaired with
acute opiate use (12-3), evidence to support the assertion that COT uniformly results in
significant driving impairment is lacking (14). From an epidemiologic perspective, there
is little substantiation that COT in isolation results in increased rate of motor vehicle
accidents (15). With regards to a commercial drivers license (CDL), Federal law (49 CFR
391.41) mandates that an individual who is applying for a CDL “has no established
medical history or clinical diagnosis of rheumatic, arthritic, orthopedic, muscular,
neuromuscular, or vascular disease which interferes with his ability to control and operate
a commercial motor vehicle safely” and “does not use a Schedule 1 controlled substance,
an amphetamine, a narcotic, or any other habit-forming drug.” However, there is an
exception in latter regulation that “ A driver may use such a substance or drug, if the
substance or drug is prescribed by a licensed medical practitioner who: (A) is familiar
with the driver's medical history and assigned duties; and (B) has advised the driver that
the prescribed substance or drug will not adversely affect the driver's ability to safely
operate a commercial motor vehicle.” While the clinical scenario does not specify if the
individual has a regular or commercial driver license, there is minimal evidence in the
described patient that sufficient impairment exists to restrict driving at present.

In summary, COT is a reasonable therapeutic maneuver for this patient. A well-trained
physiatrist should be capable of maintaining the patient on this regimen, which would
include routine monitoring for sustained analgesia, adverse effects, aberrant behaviors as
well as correlative functional status. COT should not be the totality of the patient’s
regimen but it can be a safe, effective, and appropriate element of comprehensive pain
management.

Table 1. D.I.R.E. Score (Patient Selection for Chronic Opioid Analgesia) with
scoring for proposed patient).
Factor

Explanation

Diagnosis

1 = Benign chronic condition with
minimal objective findings or no definite
medical diagnosis.
2 = Slowly progressive condition
concordant with moderate pain, or fixed

Conservative
estimate of
proposed
patient
2

Liberal
estimate of
proposed
patient
3

condition with moderate objective
findings.

Intractability

3 = Advanced condition concordant with
severe pain with objective findings.
1 = Few therapies have been tried and the
patient takes a passive role in his/her pain
management process.
2 = Most customary treatments have been
tried but the patient is not fully engaged in
the pain management process, or barriers
prevent

2

3

2

3

3

3

3

3

2

3

3 = Patient fully engaged in a spectrum of
appropriate treatments but with inadequate
response.
Risk
Psychologic

Chemical Health

Reliability

Social support

1 = Serious personality dysfunction or
mental illness interfering with care.
2 = Personality or mental health interferes
moderately.
3 = Good communication with clinic. No
significant personality dysfunction or
mental illness.
1 = Active or very recent use of illicit
drugs, excessive alcohol, or prescription
drug abuse.
2 = Chemical coper or history of chemical
depenedence in remission.
3 = No CD history. Not drug-focused or
chemically reliant.
1 = History of numerous problems:
medication misuse, missed appointments,
rarely follows through.
2 = Occasional difficulties with
compliance, but generally reliable.
3 = Highly reliable patient with meds,
appointments & treatment.
1 = Life in chaos. Little family support
and few close relationships. Loss of most
normal life roles.
2 = Reduction in some relationships and
life roles.
3 = Supportive family/close relationships.

Efficacy

Involved in work or school and no social
isolation.
1 = Poor function or minimal pain relief
despite moderate to high doses.
2 = Moderate benefit with function
improved in a number of ways

2

3

16

21

3 = Good improvement in pain and
function and quality of life with stable
doses over time.
Total

Score 7-13: Not a suitable candidate for long-term opioid analgesia
Score 14-21: May be a candidate for long-term opioid analgesia
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Adam Schreiber, DO, Responds

The Cyclical Opioid Epidemic?
Brief History of Opioids in the US
Morphine was developed as a pain killer around 1810 and greatly diminished severe pain
associated with medical operations or traumatic injuries. It also produced a numb
euphoric state. In the 1850's, morphine was available in the United States (US) and
became a treatment by physicians, however the side effect of addiction became apparent
with many Civil War soldiers; thereafter the US was plagued with a morphine epidemic.
Reputable drug companies began manufacturing over-the-counter drug kits containing
glass barreled hypodermic needle and vials of morphine or heroin packaged neatly in
attractive engraved tin cases.1 These products were marketed as the cure for all types of
physical and mental ailments ranging from alcohol withdrawal to cancer, depression,
sluggishness, coughs, colds, tuberculosis and old age.
In the 1980s, opioid use was largely limited to cancer and acute pain; it was considered
inappropriate for chronic pain management owing to concerns about adverse effects,
tolerance, dependence, and addiction. In 1986, a study concluded that chronic opioid
therapy could be safe for patients with noncancer pain.2 During the 1990s, some
clinicians encouraged the use of opioids due to concern for undertreatment of chronic
pain with the thought that opioid therapy had no ceiling and that it was appropriate to
escalate “to effect,” regardless of the amounts prescribed.3
In 1995, one hundred and forty five years after morphine became a marketable product in
the US, a long acting oxycodone (OxyContin) was “packaged neatly” with the marketing
strategy by Purdue Pharma of having low abuse potential. OxyContin was rapidly
utilized earning almost a billion dollars for Purdue Pharma in the first years of its release.
Purdue raised awareness of pain management for patients which was largely overlooked
as abuse started spreading and drug abusers discovered with manipulation of drug
delivery that it could give a quick “high”, but frequent overdosing followed.
With the paradigm shift in treatment of chronic pain, opioid prescribing in the US has
increased dramatically (108% from 1997-2004), and associated expense of 423%
inflation adjusted increase in expenditure.4 Hydrocodone is now the most commonly
prescribed medication with concomitant rise in opioid-related abuse, overdoses, and
deaths.5 Chronic pain places enormous physical, emotional and financial pressure on
society with prevalence rates ranging from 10% to 50%.6 It is estimated that 5% of
people with LBP account for 75% of the costs associated with it. With opioid overdoses
paralleling the number of prescriptions7, and population based studies indicating opioid
use for non cancer pain still results in persistent high levels of pain and poor quality of
life,8 we must admit to a cyclical opioid epidemic.

Our Patient’s Situation
With a 55 year-old on long-acting oxycodone, 80mg BID, we anticipate him needing this
for approximately 30-35 more years, and possibly requiring titration; a significant
financial expense. The side effects of cognitive difficulties, apathy, depression, and
fatigue may be major barriers to him living a healthy, and happy functional life. As he
ages, these side effects will contribute to increasing risk of falls, which carries significant
morbidities. With his opioid dependence, a commitment from the doctor to the patient
and patient to the doctor is necessary. He will need to see his physician regularly to
prevent withdrawal and therefore potential for emergency room visits (another expense
and stressor to the medical system), or the illegal activity of turning to the streets for a
supply. Another issue is diversion, are we providing him with income and the possibility
of providing others with medication illegally?
Era of evidence-based medicine
In an era of evidence-based medicine, reviews of opioid use for chronic LBP compared
with placebo or non-opioid analgesics suggest that these medications do not significantly
reduce pain and that substance abuse disorders are common. There is a lack of quality
studies on the safety and efficacy of long-term opioid therapy for LBP.9 Research shows
increased risk of opioid overdoses in patients receiving higher prescribed doses of opioids
for pain.10 There is no evidence for opioids for LBP improving functional disability or
self-assessed health status.11
Evidence indicates that chronic LBP patients are best served by a comprehensive
treatment approach12, which includes a biopsychosocial model, in contrast to isolated
opioid treatment. The biopsychosocial model views chronic pain as a complex
experience that affects and is influenced by an individual’s physical, emotional, cognitive
and social health.13 The intervention involves multidisciplinary and multimodal
treatments emphasizing adaptive self-management with goals to improve long-term
health, activity, and quality of life. These goals are attained by including patient
education, medications, physical therapy and exercise, cognitive-behavioral therapy and
social services. This approach is cost-effective and has evidence-based positive longterm results such as improving return to work, and reducing additional surgery and
health-care use.13
However third-party payers are not reimbursing many of the cost-effective components
of comprehensive pain care caused closure of these multidisciplinary pain programs and
this led to the expansion of pain clinics that deliver pharmacologic treatments and/or
spinal procedures, both of which have contributed significantly to the high health-care
costs associated with LBP without strong evidence of efficacy.3 Third-party payers
perceive opioid treatment as a quicker, less cumbersome way of efficiently treating these
patients.
How has our patient been treated and how should he be treated?
Further examination of the etiologies for low back pain in this patient is warranted but
beyond the scope of this discussion. At this point, we will assume that the treatment goal
has changed from curative to recovery of health and function. We will review actual and

possible treatments. Treatments can be broken into five categories: therapy, injections,
medications, surgery and lifestyle.14 Our patient has not responded to previous
treatments from conservative to interventional. 1) The specifics of his physical therapy
(PT) program are crucial; did he undergo an active program which progressed to a home
exercise program or just passive treatments alone? If the latter, reinitiating a wellprescribed and carried out PT program is an option. Evaluation by a pain psychologist is
necessary for his chronic pain treatment program. Other options are osteopathic
manipulation15 and acupuncture. 2) Indications for spinal injections will not be discussed
but injections were unsuccessful. Other therapeutic injection treatments are limited. 3)
Pharmacologically, he did not respond to one NSAID and cyclobenzaprine, resulting in
treatment with opioids, and he is currently on high dose long-acting oxycodone. NSAID
treatment options were not exhausted, as there is inter-individual variation among
patients in their response to a specific drug. Therefore, if chronic LBP does not respond
to one NSAID, there is a reasonable likelihood that the patient may respond to another
NSAID.16 Additionally, other medications such as tramadol should be trialed prior to
oxycodone for non-neuropathic axial LBP. 4) There is no indication for surgery. 5)
Lifestyle changes include weight loss.17 These proposed multimodal treatments should
be included in a comprehensive pain program as an ideal treatment.
The American Pain Society and American Academy of Pain Medicine published
guidelines in 2009 which stated, “chronic opioid therapy can be effective therapy for
carefully selected and monitored patients with chronic non cancer pain.”18 This
statement makes several lofty assumptions that doctors can adequately select and monitor
patients. Tools besides traditional history, physical and experience must be implemented
and monitored. The PCP has neither selected nor regulated this patient’s opioid
treatment.
The approach to a patient in this situation is difficult because he is taking high dose longacting opioids and is dependent. Preferably the referring physician should have consulted
a physiatrist earlier in this case so that management would be a dynamic process with
treatments trialed with strategies stated above before initiation or titration of opioids.
With him on long-acting oxycodone without methods of screening or monitoring puts the
consultant in a precarious situation. If the consultant is willing to take over management
then an agreement regarding titration downward with a signed drug agreement with clear
expectations of monitoring or referral for detoxification and/or buprenorphine
HCl/naloxone HCIdihydrate program is necessary. This patient has become part of the
epidemic and requires help.
Work
In regard to work, the self-reported minimal discomfort allowing him to work on the
current medication is both reassuring and concerning. He wants to continue working and
is not placing undue financial stress on the public or placing himself at risk for the
complications of long-term disability. But, he poses a risk to himself and others by
driving while being under the influence of high dose opioids. This concern will need to
be explored.

Conclusion:
The benefit versus harm profile of his current regiment is unacceptable but is the path of
least resistance to a busy clinician, especially with the enticing self-reported ability to
continue working. The responsible treatment plan to the patient, society, and the
healthcare system is to intervene towards non-opioid treatment for the patient and help
end the epidemic. This will take more than one healthcare provider. Significant time and
patient commitment is required but evidence shows that the patient will be healthier with
less risk of future complications and less long-term financial stress on the health care
system if he is treated without the use of long-term opioid medications. The second
opioid epidemic is present without end in sight. However, by meticulously intervening
with a multidisciplinary treatment program, we can help prevent this patient from being
the next victim.
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